Epcoritamab for follicular lymphoma not cured by initial treatment
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a drug called epcoritamab for people with follicular lymphoma (a type of slow-growing blood cancer) that improved but did not completely go away after standard first therapy. The goal is to see if epcoritamab can help achieve a complete remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have follicular lymphoma (grades 1-3A) that has CD20 on the surface of the cancer cells.
- You have already received at least 3 cycles of standard first treatment (a CD20 antibody like rituximab plus chemotherapy).
- Your lymphoma got better but did not completely disappear after that first treatment (you had a partial response or stable disease).
- You have measurable disease on a PET/CT scan (at least one lymph node that is visible and active).
- You are age 18 or older, with good organ function and an ECOG performance status of 0-2 (able to care for yourself).
- You have not had any anti-lymphoma therapy for at least 4 weeks before starting the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines a new immune therapy drug called epcoritamab with standard chemotherapy (R-CHOP) to treat aggressive B-cell lymphomas. It aims to see if adding this drug improves outcomes for patients who have not had prior treatment for their lymphoma.
This phase 2 trial tests whether a combination of epcoritamab plus rituximab can work as a first treatment for follicular lymphoma. It may help people whose lymphoma is causing symptoms or affecting organs, or who have bulky disease, by targeting the lymphoma cells.
This study looks at how well epcoritamab works for people with diffuse large B-cell lymphoma or follicular lymphoma who have already tried two or more treatments. Researchers want to see how it works in routine care, not in a strict research setting.
This study tests a new drug called epcoritamab (a type of immunotherapy) to see if it can keep follicular lymphoma under control, compared to 'watch and wait' (monitoring without treatment). If you have low tumor burden and haven't been treated yet, joining this trial might give you early treatment that could improve outcomes.
This trial tests a combination of three drugs (epcoritamab, zanubrutinib, and rituximab) for people with follicular lymphoma or marginal zone lymphoma that has come back after at least one prior treatment. The goal is to see if this new combination is safe and effective.
This trial tests a combination of two immune therapies—epcoritamab (a bispecific antibody) and CAR T cells—for people with large B-cell lymphoma whose cancer didn't respond to first treatment. The goal is to see if this combination works better than CAR T cells alone.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.